通过分子对接和分子动力学研究,重新利用批准的药物向CDK4/6和芳酶蛋白
Fatima A Yousif1, Abdulrahim A Alzain1, Alhafez M Alraih2
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Wad Madani, Sudan.
这项研究通过计算选12,432种化合物来确定ER+乳腺癌的潜在多向药物. 阿波莫尔芬对CDK4/6和芳酶表现出最有前途的结合亲和力,这表明它作为一种新型治疗剂的潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 计算化学的计算化学
背景情况:
- 雌激素受体阳性 (ER+) 乳腺癌是全球主要的健康问题.
- 目前的治疗向芳酶以抑制雌激素合成,但与CDK4/6抑制剂结合是关键策略.
- 了解与CDK4/6和芳酶的药物相互作用对于开发有效疗法至关重要.
研究的目的:
- 通过基于结构的药物设计,识别可以同时抑制CDK4/6和芳酶的新型化合物.
- 通过计算来选大量已批准和正在研究的药物库,以检测多目标抑制潜力.
- 评估潜在候选药物的结合 afinity 和稳定性对目标蛋白.
主要方法:
- 使用基于结构的药物设计,涉及12432种针对CDK6和芳酶的药物的分子对接.
- 使用XP对接和MM-GBSA计算进一步分析了具有有利对接分数的化合物.
- 进行了分子动力学模拟,以评估排名第一的药物-蛋白质复合物的稳定性.
主要成果:
- 四种化合物 (酸, carazolol, dantron, apomorphine) 显示出与 CDK4/6 和芳酶有良好的结合亲和力.
- 在所有三个点 (CDK6,CDK4,芳酶) 上,阿波摩菲因表现出最有利的结合自由能量.
- 分子动力学模拟证实了阿波莫尔芬和CDK6.6之间的稳定复合形成.
结论:
- 阿波莫尔芬是开发针对ER+乳腺癌中CDK4/6和芳酶的多位抑制剂的有希望的候选药物.
- 计算药物设计策略可以有效地识别复杂疾病的新型治疗剂.
- 需要进一步的实验验证,以确认已识别的化合物的治疗潜力.
更多相关视频
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
相关概念视频
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drug Discovery: Overview
